Figure 1From: Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancerSchema for multicenter pilot study of angiogenesis inhibitor therapy after neoadjuvant chemotherapy. BID, twice a day; IV, intravenously; PO, orally; qd, once daily.Back to article page